The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.
 
Yuxiang Ma
No Relationships to Disclose
 
Hongyun Zhao
No Relationships to Disclose
 
Jianhua Chen
No Relationships to Disclose
 
Zhengbo Song
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Yubiao Guo
No Relationships to Disclose
 
Gang Wu
No Relationships to Disclose
 
Wenwei Zhou
No Relationships to Disclose
 
Xiaoqing Yu
No Relationships to Disclose
 
Fangfang Gao
No Relationships to Disclose
 
Ruiguang Zhang
No Relationships to Disclose
 
Jian Fang
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Xiaoyan Lin
No Relationships to Disclose
 
Xiaohong Tian
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
 
Yanhua Tu
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
 
Juan Yu
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
 
GuangLin Liu
Employment - Ascentage Pharma
Honoraria - Ascentage Pharma
 
Yifan Zhai
Employment - Ascentage Pharma Group; Ascentage Pharma Group (I)
Leadership - Ascentage Pharma Group; Ascentage Pharma Group (I)
Stock and Other Ownership Interests - Ascentage Pharma Group; Ascentage Pharma Group (I)
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)